Arif Bilal, Chief Tech Ops Officer, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 32 trades, Bilal has exclusively sold shares, with no recorded purchases, totaling approximately $3.91 million in sell value. His transactions have been concentrated in two companies: Sarepta Therapeutics, Inc. (SRPT) and KalVista Pharmaceuticals, Inc. (KALV). Notably, the majority of his activity has been in SRPT, where he executed multiple sales in June 2024, including a significant transaction on June 25, 2024, valued at $636,270.54. Earlier in March 2024, Bilal also engaged in several smaller sales of SRPT shares, with values ranging from $29,700.84 to $60,967.94.
Bilal’s recent trades, particularly in SRPT, suggest a consistent pattern of divestment rather than accumulation. His activity in KALV has been less frequent, with no recorded sales of monetary value in recent transactions. The absence of any buying activity across both companies underscores a definitive trend toward reducing his holdings. While the reasons behind these transactions remain undisclosed, the data highlights a sustained focus on liquidating positions in SRPT, with sporadic, non-monetary activity in KALV. This pattern aligns with Bilal’s broader trading history, which reflects a strategic emphasis on selling over the past year.
AI-assisted summary